Castleark Management LLC Revance Therapeutics, Inc. Transaction History

Castleark Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$24.7 - $37.61 $571,558 - $870,295	23,140 Added 22.56%	125,727 $3.18 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $811,879 - $1.56 Million	44,220 Added 75.76%	102,587 $3.3 Million
Q4 2022 Feb 09, 2023	SELL	$18.32 - $30.66 $1.47 Million - $2.45 Million	-79,980 Reduced 57.81%	58,367 $1.08 Million
Q3 2022 Nov 15, 2022	BUY	$14.33 - $28.47 $129,457 - $257,197	9,034 Added 6.99%	138,347 $3.74 Million
Q2 2022 Aug 16, 2022	BUY	$11.52 - $20.4 $1.49 Million - $2.64 Million	129,313 New	129,313 $1.79 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

Stay updated on Castleark Management LLC with notifications on news.